Faculty

Institution

Unit

Venue

Yasir Y Elamin, MD

Thoracic/Head and Neck Medical Oncology Fellowship Director Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

Department Of Thoracic-Head And Neck Med Onc

The University of Texas MD Anderson Cancer Center

Yasir Y. Elamin, MD, is an Associate Professor and Thoracic/Head and Neck Medical Oncology Fellowship Director at The University of Texas MD Anderson Cancer Center. His research focuses on drug resistance mechanisms in EGFR-mutant non-small cell lung cancer (NSCLC), including the identification of a novel keratin 17+ drug-tolerant persister population, and on liquid biopsy correlates, such as circulating tumor DNA methylation, to predict outcomes in ALK-rearranged NSCLC. He leads trials evaluating next-generation RET inhibitors and developing multimodal digital twin frameworks for treatment response prediction. He has contributed to clinical practice guidelines on oligometastatic NSCLC and published on immunotherapy associations in pulmonary sarcomatoid carcinoma.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Yasir Y Elamin, MD

The University of Texas MD Anderson Cancer Center

Thoracic/Head and Neck Medical Oncology Fellowship Director Associate Professor

You can click a keyword to filter the displayed items

oncology cancer research radiation oncology pharmacology lung cancer thoracic oncology cancer treatment medicinal research oncogenes cancer immunotherapy cancer care molecular cancer tumor biology medicine cancer biology immunology cancer genetics cancer genomics clinical research tumor targeting therapeutic targets immunotherapy pharmacotherapy cellular therapy cancer cells anti-cancer agents cancer discovery immune checkpoint inhibitors surgical oncology novel therapies cancer management bronchial neoplasm enzyme inhibition therapeutic efficacy respiratory medicine thoracic surgery leukemia jama oncology receptor tyrosine kinases cancer imaging drug targeting cohort studies cancer risk oncogenic agent clinical mycology therapy resistance tumor suppressors clinical radiation oncology tumor heterogeneity radiation therapy metronomic chemotherapy rational drug design phase ii trial metronomic therapy clinical evidence field trial cancer growth clinical outcomes oropharynx cancer insertion location kras-mutant lung adenocarcinoma drug trials clinical immunology retrospective cohort studies treatment development neoadjuvant nivolumab egfr-mutant nsclc drug sensitivity resistance mechanisms local consolidation therapy solid tumors metastatic solid tumors selective inhibitor clinical activity primary resistance distinct patterns cancer letter cardiovascular surgery interstitial lung disease surgical pathology critical care cardiothoracic surgery patient safety metastasis urology sarcoma surgery internal medicine tumor microenvironment microsurgery transplantation proceeding lung microbiome clinical trials translational medicine radiology breast cancer kidney cancer nuclear medicine oral pathology mesothelioma outcomes research experimental medicine translational research pathology

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1138: Clinical Grade Circulating Tumor Dna Methylation Predicts Outcome to Brigatinib Plus Local Consolidative Therapy in Patients With Alk Rearranged Nsclc - Liquid Biopsy Correlates From the Brightstar Trial. Cancer Research (2026)

lung cancerepigeneticsmolecular diagnosticsmedicinecancer genomicstumor dna methylationoncologyabstract 1138oncogenescancer carebrightstar trialcancer treatmentprognostic biomarkerspathology

Abstract 6724: Oncotwin: A Multimodal Digital Twin Framework for Predicting Treatment Response and Guiding Trial Design in Alk-Rearranged Non-Small-Cell Lung Cancer.. Cancer Research (2026)

lung canceroncologyradiation oncologycancer researchtreatment responseoncogenessystems biologythoracic oncologycancer treatmentcancer discoverytrial designbronchial neoplasmabstract 6724

Abstract 7027: Multi-Lineage Evolution of Drug Resistance via a Novel Keratin 17+ Drug Tolerant Persister Population in Egfr -Mutant Nsclc.. Cancer Research (2026)

geneticsmolecular cancerdrug resistancecell biologydrug resistance analysisoncogenesmulti-lineage evolutionabstract 7027molecular biologycarcinogenesis

Abstract Ct213: A Phase I/II Study to Evaluate Ep0031 (Lunbotinib), a Next-Generation Selective Ret Inhibitor, as Monotherapy and in Combination With Chemotherapy, in Patients With Advanced Ret-Fusion-Positive Nsclc. Cancer Research (2026)

lung cancermedicineoncologynovel therapiesoncogenesabstract ct213pharmacologycancer treatmentadvanced ret-fusion-positive nsclcphase i/ii studypharmacotherapy

Sustained Response to Lorlatinib and Pemetrexed in Alk Fusion–Positive Anaplastic Thyroid Carcinoma With Multiple Distant Metastases: A Case Report. JCO Precision Oncology (2026)

metastasiscancer letteroncologyradiation oncologymolecular cancerthyroidthyroid diseaseoncogenescase reportcancer treatmentmultiple distantjama oncologypathology

Author Correction: Ctla4 Blockade Abrogates Keap1/Stk11-Related Resistance to Pd-(L)1 Inhibitors. Nature (2025)

Ferdinandos SkoulidisHaniel A. AraujoMinh Truong DoYu QianXin SunAna Galan CoboJohn T. LeMeagan MontesionRachael PalmerNadine JahchanJoseph M. JuanChengyin MinYi YuXuewen PanKathryn C. ArbourNatalie VokesStephanie T. SchmidtDavid MolkentineDwight H. OwenRegan MemmottPradnya D. PatilMelina E. MarmarelisMark M. AwadJoseph C. MurrayJessica A. HellyerJustin F. GainorAnastasios DimouChristine M. BestvinaCatherine A. ShuJonathan W. RiessCollin M. BlakelyChad V. PecotLaura MezquitaFabrizio TabbóMatthias SchefflerSubba DigumarthyMeghan J. MooradianAdrian G. SacherSally C. M. LauAndreas N. SaltosJulia RotowRocio Perez JohnsonCorinne LiuTyler StewartSarah B. GoldbergJonathan KillamZenta WaltherKurt SchalperKurtis D. DaviesMark G. WoodcockValsamo AnagnostouKristen A. MarronePatrick M. FordeBiagio RicciutiDeepti VenkatramanEliezer M. Van AllenAmy L. CummingsJonathan W. GoldmanHiram ShaishMelanie KierSharyn KatzCharu AggarwalYing NiJoseph T. AzokJeremy SegalLauren RitterhouseJoel W. NealLudovic LacroixYasir Y. ElaminMarcelo V. NegraoXiuning LeVincent K. LamWhitney E. LewisHaley N. KempBrett CarterJack A. RothStephen SwisherRichard LeeTeng ZhouAlissa PoteeteYifan KongTomohiro TakeharaAlvaro Guimaraes PaulaEdwin R. Parra CuentasCarmen BehrensIgnacio I. WistubaJianjun ZhangGeorge R. BlumenscheinCarl GayLauren A. ByersDon L. GibbonsAnne TsaoJ. Jack LeeTrever G. BivonaD. Ross CamidgeJhannelle E. GrayNatasha B. LeighlBenjamin LevyJulie R. BrahmerMarina C. Garassino

receptorscancer immunotherapykey sitepharmacologytranslational pharmacologymolecular pharmacologycellular therapyoncologyauthor correctionmedicinal chemistrydrug resistance analysissystems biologyfuture medicinal chemistrynon-pharmacological interventionsradiation oncologynovel therapiesvascular biologymedicinal researchenzyme inhibition

Chylopericardium and Chylous Effusions During Treatment With Selective Ret Inhibitors, Selpercatinib and Pralsetinib, in Non-Small Cell Lung Cancer (Nsclc).. Journal of Clinical Oncology (2025)

lung cancerbronchial neoplasmchylous effusionsoncologyradiation oncologyoncogenic agentselective ret inhibitorsthoracic oncologypharmacologycancer treatmentjama oncologypathology

CRESTONE: A Phase II Study of the Efficacy and Safety of the Her3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( Nrg1 ) Fusions. JCO Precision Oncology (2025)

cancer lettercancer immunotherapymetronomic therapyphase ii studyoncologymolecular cancerimmune checkpoint inhibitorsimmunologycancer treatmenther3 monoclonal antibodytherapeutic targetssolid tumorsmedicinal researchpathology

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. Journal of Thoracic Oncology (2025)

lung cancercancer immunotherapymolecular diagnosticsbronchial neoplasmsarcomaimmunotherapy associationsoncologyimmune checkpoint inhibitorsimmunotherapyimmunologythoracic oncologypulmonary sarcomatoid carcinomamulticenter retrospective studypathology

Longitudinal Tracking of Alk-Rearranged Nsclc From Plasma Using Circulating Tumor Rna and Circulating Tumor Dna. JTO Clinical and Research Reports (2025)

Simon HeekeSaumil GandhiHai T TranVincent K LamLauren A ByersDon L GibbonsCarl M GayMehmet AltanMara B AntonoffXiuning LeJanet TuMaliazurina B SaadMichelle PekJonathan PohKao Chin NgeowAnne TsaoTina CasconeMarcelo V NegraoJia WuGeorge R BlumenscheinJohn V HeymachYasir Y Elamin

lung cancercancer researchcancer biologycell biologycirculating-tumor rnalongitudinal trackingcirculating-tumor dnaclinical research

1
2
3
4
5
15
10 / page

Yasir Y Elamin, MD

Thoracic/Head and Neck Medical Oncology Fellowship Director Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Thoracic Surgery

Department Of Thoracic-Head And Neck Med Onc

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Yasir Y Elamin, MD

The University of Texas MD Anderson Cancer Center

Thoracic/Head and Neck Medical Oncology Fellowship Director Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

lung cancerepigeneticsmolecular diagnosticsmedicinecancer genomicstumor dna methylationoncologyabstract 1138oncogenescancer carebrightstar trialcancer treatmentprognostic biomarkerspathology

Abstract 6724: Oncotwin: A Multimodal Digital Twin Framework for Predicting Treatment Response and Guiding Trial Design in Alk-Rearranged Non-Small-Cell Lung Cancer.. Cancer Research (2026)

lung canceroncologyradiation oncologycancer researchtreatment responseoncogenessystems biologythoracic oncologycancer treatmentcancer discoverytrial designbronchial neoplasmabstract 6724

Abstract 7027: Multi-Lineage Evolution of Drug Resistance via a Novel Keratin 17+ Drug Tolerant Persister Population in Egfr -Mutant Nsclc.. Cancer Research (2026)

geneticsmolecular cancerdrug resistancecell biologydrug resistance analysisoncogenesmulti-lineage evolutionabstract 7027molecular biologycarcinogenesis

lung cancermedicineoncologynovel therapiesoncogenesabstract ct213pharmacologycancer treatmentadvanced ret-fusion-positive nsclcphase i/ii studypharmacotherapy

Sustained Response to Lorlatinib and Pemetrexed in Alk Fusion–Positive Anaplastic Thyroid Carcinoma With Multiple Distant Metastases: A Case Report. JCO Precision Oncology (2026)

metastasiscancer letteroncologyradiation oncologymolecular cancerthyroidthyroid diseaseoncogenescase reportcancer treatmentmultiple distantjama oncologypathology

Author Correction: Ctla4 Blockade Abrogates Keap1/Stk11-Related Resistance to Pd-(L)1 Inhibitors. Nature (2025)

Chylopericardium and Chylous Effusions During Treatment With Selective Ret Inhibitors, Selpercatinib and Pralsetinib, in Non-Small Cell Lung Cancer (Nsclc).. Journal of Clinical Oncology (2025)

lung cancerbronchial neoplasmchylous effusionsoncologyradiation oncologyoncogenic agentselective ret inhibitorsthoracic oncologypharmacologycancer treatmentjama oncologypathology

CRESTONE: A Phase II Study of the Efficacy and Safety of the Her3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( Nrg1 ) Fusions. JCO Precision Oncology (2025)

Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. Journal of Thoracic Oncology (2025)

Longitudinal Tracking of Alk-Rearranged Nsclc From Plasma Using Circulating Tumor Rna and Circulating Tumor Dna. JTO Clinical and Research Reports (2025)

lung cancercancer researchcancer biologycell biologycirculating-tumor rnalongitudinal trackingcirculating-tumor dnaclinical research

1
2
3
4
5
15
10 / page